HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

Explore clinical trials studying HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer. Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study

Refine in advanced search Browse all conditions

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer trial results

Recruiting

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

NCT06805812

Conditions: Abemaciclib, Breast Adenocarcinoma, Breast Cancer, +46 more
Locations: Centro di Riferimento Oncologico IRCCS Aviano, Italy

Azienda Socio Sanitaria Territoriale degli Spedali Civili Brescia, Italy

Humanitas Istituto Clinico Catanese Catania, Italy

ASST Lariana - Ospedale Sant'Anna Como, Italy

View all 24 locations

View Trial Details

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer trial results

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Related conditions